Literature Review of Cystoid Macular Edema in Iridocorneal Endothelial Syndrome and Its Response to Nepafenac 0.1%

Abstract

<jats:title>Abstract</jats:title> <jats:p><jats:bold>Background </jats:bold>Iridocorneal endothelial syndrome (ICE) is a rare disease which happens usually in women at 20-40 years of age. About 50% of patient with such disease develops glaucoma.<jats:bold>Case presentation </jats:bold>A 29-year-old woman presented in August 2015 with right eye blurring of vision for 6 months. On examination, the corneal endothelial with beaten metal appearance was noted. Right eye correctopia with iris atrophy and periphery anterior synechiae were seen. Mottled appearance of the macula which tallied with the optical coherence tomography (OCT) findings of cystoid macular edema (CME) was found. An non-steroidal anti-inflammatory drugs (NSAIDs) eye drops (NEVANACÒ Nepafenac ophthalmic suspension 0.1%) was commenced for long term. She was re-examined 2 years later in 2018. Her vision was 6/6. OCT and fundus fluorescence angiography (FFA) finding were normal.<jats:bold>Conclusion </jats:bold>The NSAIDs was the only treatment received by the patient and throughout the years, her CME has subsided. A long term use of Nepafenac 0.1% has shown to be effective in treating CME in ICE syndrome.</jats:p>